Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

New research led by Oxford BHF CRE Intermediate Transition Fellow Dr Kerstin Timm shows that a recently developed imaging technique pioneered by the Tyler Group can detect early metabolic changes in the heart caused by a commonly used chemotherapy drug, which is known to increase risk of heart failure in cancer survivors.

Chemotherapy has greatly improved cancer survival rates, especially in breast cancer patients. However, some chemotherapeutic drugs such as doxorubicin have side effects on the heart, and 5-10% of cancer survivors develop heart failure as a consequence of their cancer treatment. Unfortunately, it is not currently possible to predict which patient will suffer long-term heart problems due to their cancer therapy.

An imaging tool to screen patients regularly to check for early signs of toxicity on the heart is therefore desirable to detect any changes early and intervene with appropriate treatment. However, current clinical imaging is limited to detection of cardiac dysfunction, not prior toxic events. A recently developed imaging technique called “Hyperpolarized 13C Magnetic Resonance Imaging” allows us to assess real-time metabolic fluxes in vivo, and may therefore provide the ability to detect changes in mitochondrial metabolism and function in the doxorubicin treated heart. This technique has been pioneered in the UK in both the rodent and human heart by Professor Damian Tyler’s lab.  

In a new paper from the Tyler Group, first authored by Dr Kerstin Timm, researchers show in a clinically-relevant rat model of doxorubicin-cardiotoxicity, that non-invasive imaging with hyperpolarized magnetic resonance can detect early changes in mitochondrial metabolism that precede functional decline in the heart. The research demonstrates that the decrease in metabolic flux is due to a loss of mitochondria as well as a decrease in mitochondrial respiration. Consequently, hyperpolarized magnetic resonance imaging could potentially be translated as a screening tool into cancer patients, allowing for early intervention to reduce the incidence of chemotherapy-induced heart failure. 

Dr Timm said: "These are significant findings that could change the management of cancer survivors at risk from heart failure. Currently, heart failure medication is given to patients once they present with cardiac functional decline. Finding those patients at an earlier time point, before cardiac function is compromised, could lead to earlier therapeutic intervention and improve cardiovascular outcomes in cancer survivors."

To hear more from Dr Timm, see her blog post "Early detection of doxorubicon-induced cardiotoxicity with hyperpolarized metabolic imaging".

The full paper “Early detection of doxorubicin-induced cardiotoxicity in rats by its cardiac metabolic signature assessed with hyperpolarized MRI” is available to read in Communications Biology.

Similar stories

Earliest origins of the forming heart identified

CRE Research

The earliest known progenitor of the outermost layer of the heart has been characterised for the first time and linked to the development of other critical cell types in the developing heart in a new paper from the Srinivas group led by BHF Immediate Fellow Dr Richard Tyser.

Professor Sir Rory Collins awarded the MRC Millennium Medal 2020

CRE Research

Professor Sir Rory Collins, Head of the Nuffield Department of Population Health, and Principal Investigator and Chief Executive of UK Biobank, has been awarded the Medical Research Council (MRC) Millennium Medal 2020, the MRC’s most prestigious personal award.

Two major BHF awards to Neil Herring pave the way to new treatments for heart attack patients

CRE Research

Associate Professor Neil Herring has been awarded a Senior Clinical Research Fellowship and a Project grant from the British Heart Foundation to further critical research into the mechanisms behind heart attacks and heart failure and potential drugs to combat them. Given the 50% reduction in research investment this year from the BHF due to the impact of COVID-19, Prof Herring is to be congratulated on these awards.

Bone hormone could provide new treatment for heart rhythm disorder

CRE Publication Research

A hormone which helps regulate bone mass is also produced by the heart and could help treat people with a dangerous heart rhythm disorder, according to a new study published in the journal Nature.